Skip to main content
. Author manuscript; available in PMC: 2023 Oct 13.
Published in final edited form as: Cancer Res. 2020 Dec 3;81(4):1163–1170. doi: 10.1158/0008-5472.CAN-20-3094

Table 3.

HRs (95%CI) for 3-year and 5-year All-cause Mortality Associated with Race/ethnicity Among Female Patients with TNBC

Deaths /Patients HR (95% CI) 0 HR (95% CI) 1 HR (95% CI) 2 HR (95% CI) 3
3-year All-cause mortality
White 8,103/53,908 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Black 3,158/17,350 1.35 (0.29 to 1.40) 1.12 (1.07 to 1.17) 1.09 (1.04 to 1.13) 1.04 (0.99 to 1.09)
Hispanic 619/5,116 0.94 (0.87 to 1.02) 0.76 (0.70 to 0.83) 0.75 (0.69 to 0.81) 0.69 (0.64 to 0.76)
Asian 263/2,334 0.83 (0.74 to 0.94) 0.83 (0.73 to 0.94) 0.80 (0.71 to 0.90) 0.83 (0.73 to 0.94)
5-year All-cause mortality
White 9,923/53,908 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Black 3,702/17,350 1.31 (1.26 to 1.36) 1.09 (1.05 to 1.14) 1.07 (1.03 to 1.11) 1.03 (0.98 to 1.07)
Hispanic 753/5,116 0.95 (0.88 to 1.02) 0.77 (0.72 to 0.83) 0.75 (0.70 to 0.81) 0.70 (0.65 to 0.76)
Asian 312/2,334 0.82 (0.73 to 0.91) 0.82 (0.73 to 0.91) 0.79 (0.70 to 0.88) 0.82 (0.73 to 0.92)

Abbreviation: HR, Hazard Ratio; CI, Confidence Interval; TNBC, Triple Negative Breast Cancer.

0.

Model 0. Adjusted for age at diagnosis (continuous).

1.

Model 1. Additionally adjusted for clinical characteristics (histologic grade, histology type, tumor size, lymph node metastasis, distant metastasis, lymphovascular invasion, comorbidity).

2.

Model 2. Additionally adjusted for treatment (surgery, radiation, chemotherapy, year of diagnosis and time-to-treatment).

3.

Model 3. Additionally adjusted for factors related access to care (income, urban/rural residence, education, insurance, distance to care, facility type, and region of facility location).